$HROW
HARROW, INC. Stock $hrow

$hrow Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000149315224010518 Filed on March 19, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$34.59M	$36.36M	$130.2M
YoY Change	32.5%	78.83%	46.95%
Cost Of Revenue	$10.55M	$11.30M	$39.64M
YoY Change	27.59%	83.33%	56.17%
Gross Profit	$24.03M	$25.05M	$90.55M
YoY Change	34.78%	76.88%	43.25%
Gross Profit Margin	69.49%	68.91%	69.55%
Selling, General & Admin	$28.81M	$26.21M	$83.09M
YoY Change	81.35%	72.01%	42.66%
% of Gross Profit	119.88%	104.63%	91.76%
Research & Development	$2.149M	$3.336M	$6.652M
YoY Change	192.78%	374.54%	118.1%
% of Gross Profit	8.94%	13.32%	7.35%
Depreciation & Amortization	$2.986M	$2.883M	$11.61M
YoY Change	1227.11%	276.86%	280.1%
% of Gross Profit	12.42%	11.51%	12.82%
Operating Expenses	$30.96M	$29.55M	$90.12M
YoY Change	86.27%	85.35%	47.03%
Operating Profit	-$6.928M	-$4.495M	$431.0K
YoY Change	-672.56%	152.81%	-77.54%
Interest Expense	$5.415M	-$4.708M	$21.32M
YoY Change	14.07%	86.23%	194.37%
% of Operating Profit			4947.56%
Other Income/Expense, Net	-$6.637M	-$100.0K	-$24.14M
YoY Change	-18.47%	-198.04%	51.54%
Pretax Income	-$13.57M	-$9.683M	-$23.71M
YoY Change	95.71%	-1017.82%	69.22%
Income Tax		-$535.0K	$701.0K
% Of Pretax Income
Net Earnings	-$13.57M	-$9.148M	-$24.41M
YoY Change	104.2%	-967.11%	73.3%
Net Earnings / Revenue	-39.22%	-25.16%	-18.75%
Basic Earnings Per Share	-$0.38		-$0.75
Diluted Earnings Per Share	-$0.38	-$0.26	-$0.75
COMMON SHARES
Basic Shares Outstanding	35.36M shares	35.12M shares	32.62M shares
Diluted Shares Outstanding	35.47M shares		32.62M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$75.97M	$82.77M	$82.77M
YoY Change	182.64%	-18.74%	-18.74%
Cash & Equivalents	$68.54M	$74.09M	$74.09M
Short-Term Investments	$7.433M	$8.681M	$8.681M
Other Short-Term Assets	$2.151M	$1.753M	$9.360M
YoY Change	1722.88%	1385.59%	159.21%
Inventory	$10.81M	$10.87M	$10.87M
Prepaid Expenses
Receivables	$28.96M	$36.26M	$36.26M
Other Receivables	$228.0K	$228.0K	$228.0K
Total Short-Term Assets	$125.5M	$139.5M	$139.5M
YoY Change	142.73%	17.95%	17.95%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.389M	$3.521M	$10.31M
YoY Change	-5.49%	1.0%	-6.3%
Goodwill	$332.0K	$332.0K
YoY Change	0.0%	0.0%
Intangibles	$157.4M	$159.9M
YoY Change	3.54%	574.0%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$170.1M	$172.7M	$172.7M
YoY Change	2.57%	341.44%	341.44%
TOTAL ASSETS
Total Short-Term Assets	$125.5M	$139.5M	$139.5M
Total Long-Term Assets	$170.1M	$172.7M	$172.7M
Total Assets	$295.5M	$312.2M	$312.2M
YoY Change	35.88%	98.35%	98.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$12.57M	$21.48M	$21.48M
YoY Change	101.49%	233.56%	233.56%
Accrued Expenses	$29.07M	$27.79M	$27.79M
YoY Change	154.95%	130.05%	130.05%
Deferred Revenue	$112.0K	$75.00K
YoY Change	67.16%	-33.63%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$41.75M	$49.34M	$49.34M
YoY Change	135.79%	164.83%	164.83%
LONG-TERM LIABILITIES
Long-Term Debt	$184.1M	$183.2M	$183.2M
YoY Change	9.06%	75.83%	75.83%
Other Long-Term Liabilities	$9.429M	$9.237M	$9.237M
YoY Change	0.18%	25.98%	25.98%
Total Long-Term Liabilities	$193.6M	$192.4M	$192.4M
YoY Change	8.59%	72.55%	72.55%
TOTAL LIABILITIES
Total Short-Term Liabilities	$41.75M	$49.34M	$49.34M
Total Long-Term Liabilities	$193.6M	$192.4M	$192.4M
Total Liabilities	$235.3M	$241.8M	$241.4M
YoY Change	20.08%	85.77%	86.0%
SHAREHOLDERS EQUITY
Retained Earnings	-$147.5M	-$133.9M
YoY Change	26.98%	22.29%
Common Stock	$35.00K	$35.00K
YoY Change	16.67%	16.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$60.56M	$70.77M	$70.77M
YoY Change
Total Liabilities & Shareholders Equity	$295.5M	$312.2M	$312.2M
YoY Change	35.88%	98.35%	98.35%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$13.57M	-$9.148M	-$24.41M
YoY Change	104.2%	-967.11%	73.3%
Depreciation, Depletion And Amortization	$2.986M	$2.883M	$11.61M
YoY Change	1227.11%	276.86%	280.1%
Cash From Operating Activities	-$4.628M	$8.696M	$3.840M
YoY Change	-43.66%	-334.27%	125.22%
INVESTING ACTIVITIES
Capital Expenditures	$92.00K	$185.0K	$1.460M
YoY Change	-81.45%	-78.93%	-43.78%
Acquisitions
YoY Change
Other Investing Activities	-$18.00K	-$18.00K	-$18.00K
YoY Change	-99.99%	-102.06%	-102.11%
Cash From Investing Activities	-$110.0K	-$203.0K	-$152.6M
YoY Change	-99.92%	3960.0%	8652.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$809.0K	-18.00K	$126.5M
YoY Change	-101.3%	-100.03%	133.7%
NET CHANGE
Cash From Operating Activities	-$4.628M	8.696M	$3.840M
Cash From Investing Activities	-$110.0K	-203.0K	-$152.6M
Cash From Financing Activities	-$809.0K	-18.00K	$126.5M
Net Change In Cash	-$5.547M	8.475M	-$22.19M
YoY Change	-92.8%	-83.48%	-141.01%
FREE CASH FLOW
Cash From Operating Activities	-$4.628M	$8.696M	$3.840M
Capital Expenditures	$92.00K	$185.0K	$1.460M
Free Cash Flow	-$4.720M	$8.511M	$2.380M
YoY Change	-45.81%	-285.42%	-366.82%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001360214
CY2023Q4	us-gaap	Deferred Costs DeferredCosts		usd
CY2022Q4	HROW	Accrued Rebates And Copay Assistance AccruedRebatesAndCopayAssistance		usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Noncurrent AccountsPayableAndAccruedLiabilitiesNoncurrent		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse		usd
CY2023	HROW	Equity In Losses Of Unconsolidated Entities EquityInLossesOfUnconsolidatedEntities		usd
CY2022	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax		usd
CY2023	HROW	Gain On Sale Of Nonophthalmology Assets GainOnSaleOfNonophthalmologyAssets		usd
CY2022	HROW	Stock Issued During Period For Exercise Of Warrants StockIssuedDuringPeriodForExerciseOfWarrants		usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2023	HROW	Equity In Losses Of Unconsolidated Entities EquityInLossesOfUnconsolidatedEntities		usd
CY2022	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill		usd
CY2022	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax		usd
CY2023	HROW	Gain On Sale Of Assets GainOnSaleOfAssets		usd
CY2023	HROW	Proceeds From Sale Of Nonophthalmology Assets ProceedsFromSaleOfNonophthalmologyAssets		usd
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
CY2022	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt		usd
CY2022	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt		usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments		usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	HROW	Reclassification Of Deferred Financing Costs ReclassificationOfDeferredFinancingCosts		usd
CY2022	HROW	Accrual Of Exit Fee Related To Oaktree Loan AccrualOfExitFeeRelatedToOaktreeLoan		usd
CY2023	HROW	Purchase Of Intangible Asset Included In Accounts Payable And Accrued Expenses PurchaseOfIntangibleAssetIncludedInAccountsPayableAndAccruedExpenses		usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits		usd
CY2022Q4	HROW	Deferred Commitment Fee DeferredCommitmentFee		usd
CY2023Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent		usd
CY2022Q4	HROW	Accrued Exit Fee For Note Payable Current And Non Current AccruedExitFeeForNotePayableCurrentAndNonCurrent		usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Noncurrent AccountsPayableAndAccruedLiabilitiesNoncurrent		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod		shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential		pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements EffectiveIncomeTaxRateReconciliationTaxSettlements		pure
CY2022	HROW	Effective Income Tax Rate Reconciliation Uncertain Tax Position EffectiveIncomeTaxRateReconciliationUncertainTaxPosition		pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch		pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments		pure
CY2022Q4	HROW	Deferred Tax Assets Federal Benefit Of State Reserves DeferredTaxAssetsFederalBenefitOfStateReserves		usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	464000000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	35362642	shares
CY2023	dei	Auditor Firm AuditorFirmId	170
CY2023	dei	Auditor Name AuditorName	KMJ Corbin & Company LLP
CY2023	dei	Auditor Location AuditorLocation	Irvine, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	74085000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	96270000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	8681000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	5589000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	36261000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6249000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	10867000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	6541000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9588000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3611000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	139482000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	118260000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3521000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3486000	usd
CY2023Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	2138000	usd
CY2022Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	2112000	usd
CY2022Q4	us-gaap	Deferred Costs DeferredCosts	1950000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6785000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7513000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	159906000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	23725000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	332000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	332000	usd
CY2023Q4	us-gaap	Assets Assets	312164000	usd
CY2022Q4	us-gaap	Assets Assets	157378000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	24581000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	13771000	usd
CY2023Q4	HROW	Accrued Rebates And Copay Assistance AccruedRebatesAndCopayAssistance	18432000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5450000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4025000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	75000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	113000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	806000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	723000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	49344000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	18632000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6524000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7332000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Noncurrent AccountsPayableAndAccruedLiabilitiesNoncurrent	2713000	usd
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	183172000	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	104174000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	241753000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	130138000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29901530	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29901530	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	35000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	30000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	204635000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	137058000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-133904000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-109493000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	70766000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	27595000	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	-355000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-355000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	70411000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	27240000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	312164000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	157378000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	88595000	usd
CY2023	us-gaap	Gross Profit GrossProfit	90553000	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	83090000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	58243000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6652000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3050000	usd
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	380000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	90122000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	61293000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	431000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	1919000	usd
CY2023	us-gaap	Interest Expense InterestExpense	21324000	usd
CY2022	us-gaap	Interest Expense InterestExpense	7244000	usd
CY2022	HROW	Equity In Losses Of Unconsolidated Entities EquityInLossesOfUnconsolidatedEntities	11133000	usd
CY2023	us-gaap	Gain Loss On Investments GainLossOnInvestments	3092000	usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	-2914000	usd
CY2023	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	-5465000	usd
CY2022	HROW	Gain On Sale Of Nonophthalmology Assets GainOnSaleOfNonophthalmologyAssets	5259000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-444000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	102000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-24141000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-15930000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-23710000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14011000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	701000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	75000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-24411000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14086000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.75
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.75
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.51
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.51
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32616777	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32616777	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27460968	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27460968	shares
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	10931000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	55000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	587000	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-876000	usd
CY2022	HROW	Stock Issued During Period Value Issuance Of Common Shares From Public Offering Net Of Offering Costs StockIssuedDuringPeriodValueIssuanceOfCommonSharesFromPublicOfferingNetOfOfferingCosts	22655000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7974000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14086000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	27240000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	27240000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	64520000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	85000	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	294000	usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-13013000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	15696000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-24411000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	70411000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	70411000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-24411000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14086000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1530000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1477000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	10082000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1578000	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	728000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	610000	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	332000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	81000	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	4097000	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	782000	usd
CY2023	us-gaap	Gain Loss On Investments GainLossOnInvestments	3092000	usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	-2914000	usd
CY2022	HROW	Equity In Losses Of Unconsolidated Entities EquityInLossesOfUnconsolidatedEntities	11133000	usd
CY2023	HROW	Loss On Disposition Of Assets1 LossOnDispositionOfAssets1	168000	usd
CY2022	HROW	Loss On Disposition Of Assets1 LossOnDispositionOfAssets1	69000	usd
CY2023	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	380000	usd
CY2023	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	-5465000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	15696000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	7974000	usd
CY2022	HROW	Gain On Sale Of Assets GainOnSaleOfAssets	5259000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	30344000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1860000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4326000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2324000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5647000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3350000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	31795000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	933000	usd
CY2023	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1425000	usd
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	936000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-38000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	97000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3840000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1705000	usd
CY2022	HROW	Proceeds From Sale Of Nonophthalmology Assets ProceedsFromSaleOfNonophthalmologyAssets	6000000	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	18000	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	176000	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	30000	usd
CY2023	HROW	Payments To Acquire Marketing Authorizations And Patents PaymentsToAcquireMarketingAuthorizationsAndPatents	-151075000	usd
CY2022	HROW	Payments To Acquire Marketing Authorizations And Patents PaymentsToAcquireMarketingAuthorizationsAndPatents	-5000000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1460000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2597000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-152553000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1743000	usd
CY2023	HROW	Proceeds From Notes Payable1 ProceedsFromNotesPayable1	4961000	usd
CY2022	HROW	Proceeds From Notes Payable1 ProceedsFromNotesPayable1	31738000	usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	73552000	usd
CY2023	HROW	Payment Of Taxes For Vesting Of Restricted Stock Unit PaymentOfTaxesForVestingOfRestrictedStockUnit	13013000	usd
CY2022	HROW	Payment Of Taxes For Vesting Of Restricted Stock Unit PaymentOfTaxesForVestingOfRestrictedStockUnit	876000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	379000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	642000	usd
CY2023	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	55879000	usd
CY2023	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	59750000	usd
CY2023	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	64520000	usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	22655000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	18000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	126528000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	54141000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-22185000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	54103000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	96270000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	42167000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	74085000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	96270000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	75000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	18887000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	6480000	usd
CY2023	HROW	Reclassification Of Deferred Financing Costs ReclassificationOfDeferredFinancingCosts	1950000	usd
CY2023	HROW	Accrual Of Exit Fee Related To Oaktree Loan AccrualOfExitFeeRelatedToOaktreeLoan	2713000	usd
CY2023	HROW	Insurance Premium Financed InsurancePremiumFinanced	873000	usd
CY2022	HROW	Insurance Premium Financed InsurancePremiumFinanced	906000	usd
CY2022	HROW	Purchase Of Intangible Asset Included In Accounts Payable And Accrued Expenses PurchaseOfIntangibleAssetIncludedInAccountsPayableAndAccruedExpenses	5000000	usd
CY2023	HROW	Purchase Of Property Plant And Equipment Included In Accounts Payable And Accrued Expenses PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedExpenses	299000	usd
CY2022	HROW	Purchase Of Property Plant And Equipment Included In Accounts Payable And Accrued Expenses PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedExpenses	123000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2188000	usd
CY2023	HROW	Consolidation Basis Description ConsolidationBasisDescription	(i) entities in which it holds and/or controls, directly or indirectly, more than 50% of the voting rights, and (ii) VIEs for which the Company is deemed to be the primary beneficiary.
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84F_eus-gaap--UseOfEstimates_zISdeJron4Ql" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zaMlzvwjm9Z1">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management are, among others, allowance for credit losses, variable consideration determined based on accruals for chargebacks, administrative fees and rebates, government rebates, returns and other allowances, renewal periods and discount rates for leases, realizability of inventories, recoverability of investments, realizability of deferred tax assets, recoverability of long-lived assets and goodwill, valuations and purchase price allocations related to business combinations and asset acquisitions, fair value of loans payable, and valuation of stock-based transactions with employees and non-employees. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	371000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	73000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	73000	usd
CY2023	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	332000	usd
CY2023	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	34000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	371000	usd
CY2023	us-gaap	Minority Interest Description MinorityInterestDescription	Generally, any interest that holds less than 50% of the outstanding voting shares is deemed to be a noncontrolling interest; however, there are other factors that are considered as well, such as decision-making rights.
CY2022Q4	HROW	Deferred Financing Costs DeferredFinancingCosts	1950000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2853000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_ziTEJbVCDKFj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zufIxI51EVa4">Concentrations of Credit Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company places its cash with financial institutions deemed by management to be of high credit quality. The Federal Deposit Insurance Corporation (“FDIC”) provides basic deposit coverage with limits up to $<span id="xdx_908_eus-gaap--CashFDICInsuredAmount_iI_c20231231_z352LYl0NUxi" title="Cash, FDIC Insured Amount">250,000</span> per owner. The Company believes the majority of its cash deposits are covered under FDIC limits, however there are various accounts in which the Company has deposits in excess of FDIC limits.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q4	HROW	Accounts Receivables AccountsReceivables	371000	usd
CY2023Q4	HROW	Accounts Receivable Contractual Adjustments AccountsReceivableContractualAdjustments	14875000	usd
CY2023Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	15146000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	73000	usd
CY2022Q4	HROW	Accounts Receivable Contractual Adjustments AccountsReceivableContractualAdjustments	706000	usd
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	779000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P20Y
CY2023	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	380000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-24411000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14086000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32616777	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32616777	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27460968	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27460968	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.75
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.75
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.51
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.51
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_84F_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_ztWzpahODVii" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_ziJdpm54flr5">Reclassifications</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior period items and amounts have been reclassified to conform to the classifications used to prepare the consolidated financial statements for the current period. These reclassifications had no material impact on the Company’s consolidated financial position, results of operations, or cash flows as previously reported.</span></p>
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	130193000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	88595000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	75000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	113000	usd
CY2022	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	6000000	usd
CY2022	HROW	Closing And Transaction Costs ClosingAndTransactionCosts	55000	usd
CY2022	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	5945000	usd
CY2022	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	686000	usd
CY2022	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	5259000	usd
CY2023	HROW	Reimbursable Expenses ReimbursableExpenses	908000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	5477000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	3707000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	54000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	38000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	5336000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2796000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	10867000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	6541000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1241000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	858000	usd
CY2023Q4	us-gaap	Prepaid Royalties PrepaidRoyalties	1613000	usd
CY2022Q4	us-gaap	Prepaid Royalties PrepaidRoyalties	1165000	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	906000	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	937000	usd
CY2023Q4	HROW	Receivable Due From Related Party ReceivableDueFromRelatedParty	228000	usd
CY2022Q4	HROW	Receivable Due From Related Party ReceivableDueFromRelatedParty	139000	usd
CY2023Q4	us-gaap	Prepaid Interest PrepaidInterest	3438000	usd
CY2022Q4	us-gaap	Prepaid Interest PrepaidInterest	394000	usd
CY2023Q4	HROW	Deferred Commitment Fee DeferredCommitmentFee	409000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1753000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	118000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9588000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3611000	usd
CY2023Q4	HROW	Computer Hardware Gross ComputerHardwareGross	1322000	usd
CY2022Q4	HROW	Computer Hardware Gross ComputerHardwareGross	979000	usd
CY2023Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	936000	usd
CY2022Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	860000	usd
CY2023Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	4564000	usd
CY2022Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	4259000	usd
CY2023Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	6771000	usd
CY2022Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	6449000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13593000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12547000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10072000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9061000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3521000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3486000	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	168000	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	69000	usd
CY2023	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	1055000	usd
CY2022	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	1253000	usd
CY2023Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	2939000	usd
CY2022Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	1572000	usd
CY2023Q4	us-gaap	Capitalized Computer Software Accumulated Amortization CapitalizedComputerSoftwareAccumulatedAmortization	1268000	usd
CY2022Q4	us-gaap	Capitalized Computer Software Accumulated Amortization CapitalizedComputerSoftwareAccumulatedAmortization	793000	usd
CY2023Q4	HROW	Capitalized Computer Software Internal Use In Process CapitalizedComputerSoftwareInternalUseInProcess	467000	usd
CY2022Q4	HROW	Capitalized Computer Software Internal Use In Process CapitalizedComputerSoftwareInternalUseInProcess	1333000	usd
CY2023Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	2138000	usd
CY2022Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	2112000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	172447000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-12161000	usd
CY2023Q4	HROW	Finite Lived Intangible Assets Impairment FiniteLivedIntangibleAssetsImpairment	-380000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	159906000	usd
CY2023Q4	HROW	Finite Lived Intangible Assets Impairment FiniteLivedIntangibleAssetsImpairment	-380000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	26719000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-2368000	usd
CY2022Q4	HROW	Finite Lived Intangible Assets Impairment FiniteLivedIntangibleAssetsImpairment	-626000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	23725000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	10082000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1578000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	-9578000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	-5826000	usd
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	183172000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	13658000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	13658000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	13658000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	13309000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	12961000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	92463000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	159707000	usd
CY2023	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	usd
CY2022	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	usd
CY2023Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	21424000	usd
CY2022Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	6440000	usd
CY2023Q4	us-gaap	Accrued Insurance Current And Noncurrent AccruedInsuranceCurrentAndNoncurrent	873000	usd
CY2022Q4	us-gaap	Accrued Insurance Current And Noncurrent AccruedInsuranceCurrentAndNoncurrent	575000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	5000000	usd
CY2023Q4	HROW	Accrued Transitional Fees Current And Noncurrent AccruedTransitionalFeesCurrentAndNoncurrent	57000	usd
CY2022Q4	HROW	Accrued Transitional Fees Current And Noncurrent AccruedTransitionalFeesCurrentAndNoncurrent	453000	usd
CY2023Q4	HROW	Accrued Exit Fee For Note Payable Current And Non Current AccruedExitFeeForNotePayableCurrentAndNonCurrent	2713000	usd
CY2023Q4	HROW	Accrued Ligitation Settlements Current And Noncurrent AccruedLigitationSettlementsCurrentAndNoncurrent	249000	usd
CY2022Q4	HROW	Accrued Ligitation Settlements Current And Noncurrent AccruedLigitationSettlementsCurrentAndNoncurrent	49000	usd
CY2023Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	1978000	usd
CY2022Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	1254000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	27294000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	13771000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	24581000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	13771000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Noncurrent AccountsPayableAndAccruedLiabilitiesNoncurrent	2713000	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	192750000	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	110000000	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	104174000	usd
CY2023	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.1093	pure
CY2022	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0897	pure
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	21201000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	20590000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	159896000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	45030000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	246717000	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	53967000	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	192750000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	-9578000	usd
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	183172000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.066	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.066	pure
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y4M24D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y10M24D
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	1231000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	925000	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	1232000	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	1117000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1261000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1093000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1114000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	972000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	657000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	5173000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	10270000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2940000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	7330000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	806000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6524000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	4580000	usd
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	2008000	usd
CY2023	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit	1.47
CY2023	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit	25.86
CY2023Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	2711317	shares
CY2023	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P4Y
CY2023Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	6.25
CY2023Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	2432826	shares
CY2023Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	5.55
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	493806	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	7.99
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	128174	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	11.68
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	175643	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	8.67
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	83308	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	6.84
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	363029	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	9.23
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	665288	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	7.57
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	65615	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.62
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	237098	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	6.67
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	493806	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	7.99
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15696000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7974000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	701000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	75000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	701000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	75000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	701000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	75000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0077	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0282	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.0802	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.1993	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.0134	pure
CY2023	HROW	Effective Income Tax Rate Reconciliation Excess Employee Remuneration EffectiveIncomeTaxRateReconciliationExcessEmployeeRemuneration	-0.3083	pure
CY2022	HROW	Effective Income Tax Rate Reconciliation Excess Employee Remuneration EffectiveIncomeTaxRateReconciliationExcessEmployeeRemuneration	-0.2815	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements EffectiveIncomeTaxRateReconciliationTaxSettlements	0.0452	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.0043	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.0018	pure
CY2023	HROW	Effective Income Tax Rate Reconciliation Uncertain Tax Position EffectiveIncomeTaxRateReconciliationUncertainTaxPosition	-0.1171	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.0053	pure
CY2023	HROW	Effective Income Tax Rate Reconciliation Provision To Return True Ups EffectiveIncomeTaxRateReconciliationProvisionToReturnTrueUps	0.0172	pure
CY2022	HROW	Effective Income Tax Rate Reconciliation Provision To Return True Ups EffectiveIncomeTaxRateReconciliationProvisionToReturnTrueUps	0.0206	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0297	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.0571	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.0622	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0288	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0053	pure
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	4669000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9401000	usd
CY2023Q4	HROW	Deferred Tax Asset T Ax Credit Xarry Forwards Depreciation And Amortization DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization	1637000	usd
CY2022Q4	HROW	Deferred Tax Asset T Ax Credit Xarry Forwards Depreciation And Amortization DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization	2387000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	854000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	349000	usd
CY2023Q4	HROW	Deferred Tax Assets Research And Development DeferredTaxAssetsResearchAndDevelopment	220000	usd
CY2022Q4	HROW	Deferred Tax Assets Research And Development DeferredTaxAssetsResearchAndDevelopment	90000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1059000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	945000	usd
CY2023Q4	HROW	Income Tax Basis Difference In Related Party Two IncomeTaxBasisDifferenceInRelatedPartyTwo	583000	usd
CY2022Q4	HROW	Income Tax Basis Difference In Related Party Two IncomeTaxBasisDifferenceInRelatedPartyTwo	1684000	usd
CY2023Q4	HROW	Income Tax Basis Difference In Investments IncomeTaxBasisDifferenceInInvestments	3405.000	usd
CY2022Q4	HROW	Income Tax Basis Difference In Investments IncomeTaxBasisDifferenceInInvestments	4240000	usd
CY2023Q4	HROW	Deferred Tax Assets Federal Benefit Of State Reserves DeferredTaxAssetsFederalBenefitOfStateReserves	88000	usd
CY2023Q4	HROW	Deferred Tax Assets Limitations DeferredTaxAssetsLimitations	2893000	usd
CY2022Q4	HROW	Deferred Tax Assets Limitations DeferredTaxAssetsLimitations	536000	usd
CY2023Q4	HROW	Deferred Tax Assets Tax Deferred Capitalized Expenses Limitations DeferredTaxAssetsTaxDeferredCapitalizedExpensesLimitations	1261000	usd
CY2022Q4	HROW	Deferred Tax Assets Tax Deferred Capitalized Expenses Limitations DeferredTaxAssetsTaxDeferredCapitalizedExpensesLimitations	594000	usd
CY2023Q4	HROW	Deferred Tax Assets Tax Deferred Lease Liability Expense Limitations DeferredTaxAssetsTaxDeferredLeaseLiabilityExpenseLimitations	1710000	usd
CY2022Q4	HROW	Deferred Tax Assets Tax Deferred Lease Liability Expense Limitations DeferredTaxAssetsTaxDeferredLeaseLiabilityExpenseLimitations	2427000	usd
CY2023Q4	HROW	Deferred Tax Assets Tax Deferred Right Of Use Assets Expense Limitations DeferredTaxAssetsTaxDeferredRightOfUseAssetsExpenseLimitations	1582000	usd
CY2022Q4	HROW	Deferred Tax Assets Tax Deferred Right Of Use Assets Expense Limitations DeferredTaxAssetsTaxDeferredRightOfUseAssetsExpenseLimitations	2263000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	15631000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	17022000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15631000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	17022000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1391000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1182000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	8596000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	26134000	usd
CY2023	HROW	State Net Operating Loss Expiration Date StateNetOperatingLossExpirationDate	2036
CY2023	HROW	Federal Net Operating Loss Carryforward Description FederalNetOperatingLossCarryforwardDescription	the Company has federal net operating loss carryforward of $4,936,000 generated after 2017 that can be carried over indefinitely and may be used to offset up to 80% of federal taxable income
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2853000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	2853000	usd
CY2023Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	40000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	36000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	2817000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2853000	usd
CY2023	HROW	Percentage Of Salary Deposits In Tax Deferred Investment Account PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount	1	pure
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.04	pure
CY2023	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	594000	usd
CY2022	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	397000	usd

Files In Submission

Name	View Source	Status
0001493152-24-010518-index-headers.html	Edgar Link	pending
0001493152-24-010518-index.html	Edgar Link	pending
0001493152-24-010518.txt	Edgar Link	pending
0001493152-24-010518-xbrl.zip	Edgar Link	pending
ex10-46.htm	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex4-1.htm	Edgar Link	pending
ex97.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
hrow-20231231.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
hrow-20231231_cal.xml	Edgar Link	unprocessable
hrow-20231231_def.xml	Edgar Link	unprocessable
hrow-20231231_lab.xml	Edgar Link	unprocessable
hrow-20231231_pre.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HROW
HARROW, INC. Stock $hrow

2024 Q1 Form 10-K Financial Statement

#000149315224010518 Filed on March 19, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HROW HARROW, INC. Stock $hrow

2024 Q1 Form 10-K Financial Statement

#000149315224010518 Filed on March 19, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HROW
HARROW, INC. Stock $hrow